Indian stocks: Visit www.stage2stocks.com →

Biodesix, Inc.

Stage 2 · Advancing · week 18

As of Oct 22, 2026, Biodesix is in Stage 2, the uptrend phase, now in week 18 (since Jun 23, 2026). It closed at $23.94, 21.8% below its 52-week high and above its 200-day average, which is rising.

Biodesix, Inc. operates as a diagnostic solutions company. More about the company

$23.94
+0.04% today
$253M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is BDSX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 36w
S2 16w
S2 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 11w → S4 3w → S3 2w → S2 1w → S3 3w → S2 9w → S3 5w → S4 9w → S1 6w → S2 13w → S3 4w → S4 36w → S1 10w → S4 8w → S1 2w → S4 2w → S1 1w → S2 16w → S3 5w → S2 17w current
Total tracked: 164 weeks across 21 stage runs.

BDSX among Diagnostics & Research2nd of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
vs 52W High
-21.8%
$5.46 lo$30.60 hi
21.8% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 18
1w13w26w
Week 18, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
31.4%
200 DMA: $18.21 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.33x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-18.3%
3M
+8.8%
6M
+140.4%
YTD
+270.6%
1Y
+250.5%
Scan Membership
Breakout Watch
Latest: 2024-08-01
4 appearances in last 60 days. First seen: 2023-01-19.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 18 · Vol 1.33x
2026-10-21S2
Wk 17 · Vol 0.49x
2026-10-20S2
Wk 17 · Vol 0.46x
2026-10-19S2
Wk 17 · Vol 0.51x
2026-10-16S2
Wk 17 · Vol 0.72x
2026-10-15S2
Wk 17 · Vol 0.32x
2026-10-14S2
Wk 16 · Vol 0.73x
2026-10-13S2
Wk 16 · Vol 0.48x
2026-10-12S2
Wk 16 · Vol 0.37x
2026-10-09S2
Wk 16 · Vol 0.42x
2026-10-08S2
Wk 16 · Vol 0.87x
2026-10-07S2
Wk 15 · Vol 0.52x
Moving averages & range
50 DMA
$26.61
200 DMA
$18.21
52W High
$30.60
52W Low
$5.46
5D Low
$23.40
Resistance levels (recent highs)
20d High
$30.42
60d High
$30.60
120d High
$30.60
250d High
$30.60
Next resistance
+27.1%
to 20d High
ROE
-540.0%
Profit margin -27.0%
Dividend Yield
0.00%
P/B 27.6

Biodesix: quick answers

What stage is Biodesix in?

As of Oct 22, 2026, Biodesix (BDSX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 23, 2026 and is in week 18. What the four stages mean

Is Biodesix in an uptrend?

Yes. Biodesix is in a Stage 2 uptrend. It trades 31.4% above its 200-day average, which is rising.

How far is Biodesix from its 52-week high?

Biodesix closed at $23.94 on Oct 22, 2026, 21.8% below its 52-week high of $30.60. Its 52-week low is $5.46.

How has Biodesix performed over the past year?

As of Oct 22, 2026, Biodesix is up 250.5% over the past year and up 270.6% so far in 2026.

Which sector and industry is Biodesix in?

Biodesix is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.